COMP <GO>
EVH vs CRAI // DIVIDEND YIELD & FCF PAYOUT SAFETY
Evolent Health Inc (Class A) (NYSE) VS. CRA International Inc. (NASDAQ) • 15-METRIC TALLY: EVH 1
— CRAI 8
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: CRAI
LAST: $4.30 (+1.18%) • MKT CAP: $480.5M
dividend-safety
0.00%
LAST: $196.08 (-0.35%) • MKT CAP: $1.24B
dividend-safety
1.12%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EVH VS. CRAI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EVH | CRAI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 21.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -26.30% | 33.60% | -59.90 | CRAI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 14.1x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 8.08% | 1.50% | +6.58 | EVH | /fcf-yield <GO> |
| Operating Margin | -21.90% | 11.10% | -33.00 | CRAI | /operating-margins <GO> |
| Net Profit Margin | -30.90% | 7.30% | -38.20 | CRAI | /net-margins <GO> |
| Revenue Growth (YoY) | -26.60% | 9.30% | -35.90 | CRAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 1.12% | -1.12 | CRAI | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 5/9 | -1.00 | CRAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.8 | 66.9 | -19.10 | CRAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 20.9x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $480.5M | $1.24B | -$754.6M | CRAI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EVH REV | CRAI REV | EVH GROSS % | CRAI GROSS % | EVH FCF | CRAI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.88B | $751.6M | 21.3% | — | $38.8M | $18.6M |
| FY 2024 | $2.55B | $687.4M | 14.4% | — | $18.8M | $33.1M |
| FY 2023 | $1.96B | $624.0M | — | — | $142.6M | $60.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EVH // BETA —
CRAI // BETA —